Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations

被引：4
|
作者：
Hendrickson, Andrea E. Wahner [1 ]
Bakkum-Gamez, Jamie N. [2 ]
Couch, Fergus J. [3 ]
Ghosh, Karthik [4 ]
Boughey, Judy C. [5 ]
机构：
[1] Mayo Clin, Dept Med Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[4] Mayo Clin, Dept Med, Rochester, MN USA
[5] Mayo Clin, Dept Surg, Rochester, MN USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2017年 / 24卷 / 11期
关键词：
TAMOXIFEN; CARRIERS;
D O I：
10.1245/s10434-017-5999-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3107 / 3109
页数：3
相关论文
共 50 条
  • [11] BRCA1 and BRCA2 Mutations and Breast Cancer
    Narod, Steven A.
    Salmena, Leonardo
    [J]. DISCOVERY MEDICINE, 2011, 12 (66) : 445 - 453
  • [12] Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Liede, A
    Malik, IA
    Aziz, Z
    de los Rios, P
    Kwan, E
    Narod, SA
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) : 595 - 606
  • [13] High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients
    Al-Joharah Alhuqail
    Areej Alzahrani
    Hannah Almubarak
    Sarah Al-Qadheeb
    Lamyaa Alghofaili
    Nisreen Almoghrabi
    Hamed Alhussaini
    Ben Ho Park
    Dilek Colak
    Bedri Karakas
    [J]. Breast Cancer Research and Treatment, 2018, 168 : 695 - 702
  • [14] Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
    Petrucelli, Nancie
    Daly, Mary B.
    Feldman, Gerald L.
    [J]. GENETICS IN MEDICINE, 2010, 12 (05) : 245 - 259
  • [15] Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
    Moran, A.
    O'Hara, C.
    Khan, S.
    Shack, L.
    Woodward, E.
    Maher, E. R.
    Lalloo, F.
    Evans, D. G. R.
    [J]. FAMILIAL CANCER, 2012, 11 (02) : 235 - 242
  • [16] Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
    Rebbeck, Timothy R.
    Mitra, Nandita
    Wan, Fei
    Sinilnikova, Olga M.
    Healey, Sue
    McGuffog, Lesley
    Mazoyer, Sylvie
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    Nathanson, Katherine L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (13): : 1347 - 1361
  • [17] PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2
    Ramanathan, R.
    Wainberg, Z.
    Mina, L.
    Byers, L.
    Chugh, R.
    Zhang, C.
    Henshaw, J.
    Dorr, A.
    de Bono, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S13 - S13
  • [18] High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients
    Alhuqail, Al-Joharah
    Alzahrani, Areej
    Almubarak, Hannah
    Al-Qadheeb, Sarah
    Alghofaili, Lamyaa
    Almoghrabi, Nisreen
    Alhussaini, Hamed
    Park, Ben Ho
    Colak, Dilek
    Karakas, Bedri
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (03) : 695 - 702
  • [19] Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
    A. Moran
    C. O’Hara
    S. Khan
    L. Shack
    E. Woodward
    E. R. Maher
    F. Lalloo
    D. G. R. Evans
    [J]. Familial Cancer, 2012, 11 : 235 - 242
  • [20] BRCA1 and BRCA2 Mutations in Ovarian Cancer Reply
    Zhang, Wei
    Yang, Da
    Sood, Anil K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 360 - 361
12345